02_05 Management of Metastatic Hormone Positive Breast Cancer

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1. Endocrine Resistance: Definition and Mechanism

2. Role of AI with and without CDK4/6 inhibitors

3. Later line management of metastatic disease

4. Informative Censoring and the BOLERO-2 trial

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Tannock I et al. Ann Oncol. 2020;31(3):331-333. doi:10.1016/J.ANNONC.2019.11.017

2. André F et al. NEJM. 2019;380(20):1929-1940. doi:10.1056/NEJMOA1813904/

3. Tannock IF et al.. Annals of Oncology. 2014;25(10):2096. doi:10.1093/annonc/mdu371

4. Piccart M et al. Ann Oncol. 2014;25(12):2357-2362. doi:10.1093/ANNONC/MDU456

5. Baselga J et al. NEJM. 2012;366(6):520-529. doi:10.1056/NEJMOA1109653

6. Gao JJ et al. Lancet Oncol. 2020;21(2):250-260. doi:10.1016/S1470-2045(19)30804-6

7. Howie LJ et al. JCO. 2019;37(36):3475-3483. doi:10.1200/JCO.18.02217

8. Im SA et al. NEJM. 2019;381(4):307-316. doi:10.1056/NEJMOA1903765/

9. Hortobagyi GN et al. NEJM. 2022;386(10):942-950. doi:10.1056/NEJMOA2114663/

10. Finn RS et al. NEJM. 2016;375(20):1925-1936. doi:10.1056/NEJMOA1607303/

11. Turner NC et al. NEJM. 2018;379(20):1926-1936. doi:10.1056/NEJMOA1810527/

12. Robertson JFR et al. Lancet. 2016;388(10063):2997-3005. doi:10.1016/S0140-6736(16)32389-3

13. Mauri D et al. J Natl Cancer Inst. 2006;98(18):1285-1291. doi:10.1093/JNCI/DJJ357

14. Lindström LS et al. JCO. 2012;30(21):2601-2608. doi:10.1200/JCO.2011.37.2482

15. Mouridsen H et al. JCO. 2001;19(10):2596-2606. doi:10.1200/JCO.2001.19.10.2596

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology